Prostate Cancer Pipeline Outlook Report 2024 (Updated)

DelveInsight's, "Prostate Cancer Pipeline Insight 2024" report provides comprehensive insights about 140+ Prostate Cancer companies and 150+ Prostate Cancer pipeline drugs in Prostate Cancer pipeline landscape. It covers the Prostate Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Prostate Cancer Pipeline Report
• Over 140+ Prostate Cancer companies are evaluating 150+ Prostate Cancer pipeline therapies in various stages of development, and their anticipated acceptance in the Prostate Cancer market would significantly increase market revenue.
• The leading Prostate Cancer Companies working in the market include Janssen Pharmaceutical, POINT Biopharma, Tavanta Therapeutics, Exelixis, Astellas Pharma Inc., Antev, ORCA Therapeutics, Regeneron Pharmaceuticals, Silenseed LTD, Lantheus, Pantarhei Oncology, Zenith Epigenetics, Merck Sharp & Dohme, Bivision Pharmaceuticals, Oncternal Therapeutics, Amunix, FutureChem, Amgen, Taiho Oncology, Harpoon Therapeutics, Arvinas Androgen Receptor Inc., BioNTech SE, Nova Therapeutics, Qilu Pharmaceutical Co., Ltd., Ambrx, Janssen Research & Development, LLC, ORIC Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Clarity Pharmaceuticals Ltd., Vaccitech (UK) Limited, Orion Pharma, Hinova Pharmaceuticals, and Cellbion Co., Ltd., and others.
• Promising Prostate Cancer Pipeline Therapies in the various stages of development include Capivasertib, Enzalutamide, Abiraterone, rosuvastatin, digoxin, 18F-PSMA-1007, rhPSMA-7.3 (18F) Injection, and others.
• April 2024: AstraZeneca announced a study of Phase 1 & 2 clinical trials for AZD5305, Enzalutamide, Abiraterone Acetate and Darolutamide. This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of AZD5305 when given in combination with new hormonal agents (NHAs) in patients with Metastatic Prostate Cancer.
• April 2024: Pfizer announced a study of Phase 2 clinical trials for Talazoparib. The purpose of this international, phase 2, open-label, response rate study of talazoparib is to assess the efficacy and safety of talazoparib in men with DNA repair defects metastatic castration-resistant prostate cancer (CRPC) who previously received taxane-based chemotherapy and progressed on at least 1 novel hormonal agent (enzalutamide and/or abiraterone acetate/prednisone).

Request a sample and discover the recent advances in Prostate Cancer Treatment Drugs @ Prostate Cancer Infection Pipeline Outlook Report- https://www.delveinsight.com/sample-request/prostate-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

In the Prostate Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Prostate Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Prostate Cancer Overview
Prostate Cancer begins when cells in the prostate gland start to grow out of control. The prostate is a gland found only in males. It makes some of the fluid that is part of semen. Prostate cancer is mainly caused due to the changes in the DNA. These changes occur because of mutation in DNA. Prostate cancer is diagnosed when the cancer stage advances and symptoms are visible. However early screening test can be performed to find cancer in people before they show any symptoms.

Find out more about Prostate Cancer Treatment Landscape @ Drugs for Prostate Cancer Treatment- https://www.delveinsight.com/sample-request/prostate-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Prostate Cancer Emerging Drugs Profile

• Niraparib: Janssen Research & Development
Niraparib is an orally administered selective poly ADP-ribose polymerase (PARP) inhibitor. In April 2016, Janssen entered a worldwide (except Japan) collaboration and license agreement with TESARO for exclusive rights to niraparib in prostate cancer. In the US, niraparib is indicated for the treatment of adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Niraparib is currently marketed as ZEJULA by TESARO, an oncology-focused business within GSK. The drug is currently being evaluated in Phase III clinical trials to treat patients with metastatic castration-resistant prostate cancer (mCRPC) and metastatic hormone-sensitive prostate cancer (mCSPC).

• ZEN 3694: Zenith Epigenetics
ZEN-3694 is an orally bioavailable, potent, small molecule BET inhibitor that selectively binds to both bromodomains of the BET proteins. The drug candidate was discovered and developed from a BET bromodomain inhibitor platform. Bromodomain and Extra-Terminal domain (BET) family of proteins (BRD2, BRD3, BRD4, and BRDT) can bind acetylated lysines through their tandem bromodomains to promote gene transcription. BET bromodomain inhibitors (BETi) target super enhancers and inhibit several programs involved in tumorigenesis such as proliferation, metastasis, invasion, and immune evasion. The drug is currently being evaluated in the Phase II stage of its development for the treatment of Prostate cancer.

• Ladiratuzumab vedotin: Seagen
Ladiratuzumab vedotin is a novel investigational ADC targeted to LIV-1. Most metastatic breast cancers express LIV-1, which also has been detected in several other cancers, including lung, head and neck, esophageal and gastric. Ladiratuzumab vedotin utilizes Seattle Genetics' proprietary ADC technology and consists of a LIV-1-targeted monoclonal antibody linked to a potent microtubule-disrupting agent, monomethyl auristatin E (MMAE) by a protease-cleavable linker. This novel ADC is designed to bind to LIV-1 on cancer cells and release the cell-killing agent into target cells upon internalization. Ladiratuzumab vedotin may also cause antitumor activity through other mechanisms, including activation of an immune response by induction of immunogenic cell death. Currently, the drug is in the Phase II stage of its development for the treatment of Prostate Cancer.

• FOR46: Fortis Therapeutics
FOR46 is a fully human antibody conjugated to a potent payload, depending on the indication. Fortis Therapeutics is developing FOR46, a novel antibody-drug conjugate (ADC) against CD46, for the treatment of metastatic castration-resistant prostate cancer and late-stage multiple myeloma. The Company is also evaluating additional indications for FOR46. Currently, the drug is in the Phase I/II stage of its development for the treatment of Prostate Cancer.

• REGN5678: Regeneron Pharmaceuticals
REGN5678 is designed to bind to CD28 on cytotoxic T-lymphocytes (CTLs) and PSMA on tumor cells. By binding to the costimulatory T-cell-specific surface glycoprotein and tumor-associated antigen, the drug candidate could activate CTLs and direct them to attack cancer cells. Regeneron identified the targeting of CD28 on previously activated T cells as a way to reduce toxicity compared to CD3 bispecifics. Currently, the drug is in the Phase I/II stage of its development for the treatment of Prostate Cancer.

Prostate Cancer Pipeline Therapeutics Assessment
There are approx. 140+ key companies which are developing the therapies for Prostate Cancer. The companies which have their Prostate Cancer drug candidates in the most advanced stage, i.e. phase III include, Janssen Research & Development.

DelveInsight's Prostate Cancer Pipeline Report covers around 150+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Prostate Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.

Prostate Cancer Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Learn more about the emerging Prostate Cancer Pipeline Therapies @ Prostate Cancer Clinical Trials Assessment- https://www.delveinsight.com/sample-request/prostate-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Prostate Cancer Pipeline Report
• Coverage- Global
• Prostate Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Prostate Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Prostate Cancer Companies- Merck & Co, Pfizer, Orion, Zenith Epigenetics, ESSA Pharma, RhoVac, AstraZeneca, Blue Earth Diagnostics, Advaxis, Inc., Emtora Biosciences, Tracon Pharmaceuticals Inc., Bristol-Myers Squibb, Laekna Limited, Bracco Diagnostics, Inc., Arvinas Inc., Epizyme, Harpoon Therapeutics, Plexxikon, Regeneron Pharmaceuticals, Veru Inc., Jiangsu Hengrui Medicine Co., Eli Lilly and Company, Exelixis, Luye Pharma Group, Amgen, Innocrin Pharmaceutical, Genovax, Cancer Targeted Technology, Bayer, Nymox Pharmaceutical, Matrix Biomed, Tavanta Therapeutics, Fortis Therapeutics, Inc., Janssen Research & Development, LLC, Clarity Pharmaceuticals, Leap Therapeutics, Hinova pharmaceuticals, Allife Medical Science and Technology, Vaccitech, Cardiff Oncology, Suzhou Kintor Pharmaceuticals, Teneobio, Inc., and others.
• Prostate Cancer Pipeline Therapies- Capivasertib, Enzalutamide, Abiraterone, rosuvastatin, digoxin, 18F-PSMA-1007, rhPSMA-7.3 (18F) Injection, and others.

Dive deep into rich insights for new drugs for Prostate Cancer treatment, Visit @ Prostate Cancer Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/prostate-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Prostate Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Prostate Cancer- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Niraparib: Janssen Research & Development
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. ZEN 3694: Zenith Epigenetics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. FOR46: Fortis Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Product Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Prostate Cancer Key Companies
21. Prostate Cancer Key Products
22. Prostate Cancer- Unmet Needs
23. Prostate Cancer- Market Drivers and Barriers
24. Prostate Cancer- Future Perspectives and Conclusion
25. Prostate Cancer Analyst Views
26. Prostate Cancer Key Companies
27. Appendix

For further information on the Prostate Cancer pipeline therapeutics, reach out to Prostate Cancer Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/prostate-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

List of Important Links-

https://faceblox.mn.co/posts/54148443
https://edpt204w19.mn.co/posts/54148617
https://monewment.mn.co/posts/54148939
https://flexi-vegan.mn.co/posts/54149020
https://network-4526.mn.co/posts/54149059
https://redline-rp.mn.co/posts/54149156
https://sparklabsglobal.mn.co/posts/54149234
https://ajodance.mn.co/posts/54149267
https://datingwithprettygirls.mn.co/posts/54149313
https://dazed.mn.co/posts/54149356
https://moons.mn.co/posts/54149384
https://network-339477.mn.co/posts/54149409
https://match-ideas.mn.co/posts/54149766
https://ceo-codes.mn.co/posts/54149864
https://thinkinvestments.mn.co/members/23360451
https://spoder.mn.co/posts/54150026
https://network-64869.mn.co/posts/54150082
https://network-4448412.mn.co/posts/54150397
https://network-90620.mn.co/posts/54150432
https://network-16648.mn.co/posts/54150462
https://a-d-n.mn.co/posts/54150499
https://fcmcommunity.mn.co/posts/54280862
https://good-stewards.mn.co/posts/54280899
https://listening-works.mn.co/posts/54280919
https://network-20540.mn.co/posts/54280968
https://healing-communities-njde.mn.co/posts/54281001
https://runite.mn.co/posts/54281382
https://jasa-seo.mn.co/posts/54281443
https://louhangaround.mn.co/posts/54281497
https://onwayassociation.mn.co/posts/54281510
https://shaman-leaders.mn.co/posts/54281625
https://virtuous-rubies.mn.co/posts/54281637
https://extinct-networks.mn.co/posts/54281691
https://kingnobleblacksupremacy.mn.co/posts/54282200
https://ledpanellights.mn.co/posts/54282336
https://diy-vision.mn.co/posts/54282407
https://digimac-technologies.mn.co/posts/54282475
https://network-89593.mn.co/posts/54282548
https://tdcommunitynetworks.mn.co/posts/54282663
https://machine-parts-toolbox.mn.co/posts/54282718
https://wecanchat.mn.co/posts/exploring-the-dynamics-of-the-uveitis-market-insights-by-delveinsight
https://jointsnmotion-hub.mn.co/posts/54283557
https://artisthub.mn.co/posts/54283657
https://global-non-profit-network.mn.co/posts/54283837
https://jointsnmotion-hub.mn.co/posts/54283943
https://network-5674633.mn.co/posts/54284190
https://where-this-business-and-businesses.mn.co/posts/54284238
https://travelwithme.social/read-blog/34900

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:
https://www.delveinsight.com/report-store/medical-marijuana-market-insight
https://www.delveinsight.com/report-store/ranibizumab-biosimilars-insight
https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market

This release was published on openPR.